Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.

Also called NCT03940183

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 254 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03940183
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03940183. Randomized; quadruple masking; primary purpose treatment. Start 2019-07-08 (actual); primary completion 2020-12-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Trelagliptin Succinate
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03940183
Content hash
444bb2da20a75a8e6861e59d4ae2797dd63db1d3ae0a9fdf5f47cd88633eb3d2